5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 5 of 5 clinical reviews.
Evidence-based guide to low-dose naltrexone (LDN) dosing, pharmacogenomics, and clinical considerations specific to Black and African ancestry patients, reviewed by the HealthRX.com medical team.
Evidence-based guide to Low-Dose Naltrexone (LDN) dosing in Hispanic and Latino patients, covering CYP2D6 pharmacogenomics, metabolic considerations, and clinical monitoring protocols.
A detailed clinical review of pharmacogenomic and pharmacokinetic factors that may explain efficacy differences with low-dose naltrexone (LDN) in East Asian patients, including CYP2D6/CYP2C19 polymorphisms, dosing guidance, and what the current evidence actually shows.
East Asian patients metabolize naltrexone differently due to CYP2D6 and OPRM1 A118G variant frequencies. Learn how to adjust low-dose naltrexone (LDN) dosing, what the pharmacogenomic evidence says, and what clinicians should monitor.
A clinical deep-dive into how ancestry-related pharmacogenomics, opioid receptor variants, and trial enrollment gaps affect low-dose naltrexone outcomes in Black and African ancestry patients.